17-43049179-A-G

Variant summary

Our verdict is Uncertain significance. The variant received 1 ACMG points: 2P and 1B. PM1BP6

The NM_007294.4(BRCA1):​c.5348T>C​(p.Met1783Thr) variant causes a missense change. The variant allele was found at a frequency of 0.0000929 in 1,614,158 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M1783I) has been classified as Uncertain significance.

Frequency

Genomes: š‘“ 0.00052 ( 0 hom., cov: 31)
Exomes š‘“: 0.000049 ( 0 hom. )

Consequence

BRCA1
NM_007294.4 missense

Scores

5
11
2

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:4B:13

Conservation

PhyloP100: 5.13

Publications

36 publications found
Variant links:
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
BRCA1 Gene-Disease associations (from GenCC):
  • breast-ovarian cancer, familial, susceptibility to, 1
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
  • Fanconi anemia, complementation group S
    Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
  • pancreatic cancer, susceptibility to, 4
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • hereditary breast ovarian cancer syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 1 ACMG points.

PM1
In a hotspot region, there are 22 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 8 benign, 77 uncertain in NM_007294.4
BP6
Variant 17-43049179-A-G is Benign according to our data. Variant chr17-43049179-A-G is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 37659.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_007294.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
BRCA1
NM_007294.4
MANE Select
c.5348T>Cp.Met1783Thr
missense
Exon 21 of 23NP_009225.1
BRCA1
NM_001407581.1
c.5414T>Cp.Met1805Thr
missense
Exon 22 of 24NP_001394510.1
BRCA1
NM_001407582.1
c.5414T>Cp.Met1805Thr
missense
Exon 22 of 24NP_001394511.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
BRCA1
ENST00000357654.9
TSL:1 MANE Select
c.5348T>Cp.Met1783Thr
missense
Exon 21 of 23ENSP00000350283.3
BRCA1
ENST00000471181.7
TSL:1
c.5411T>Cp.Met1804Thr
missense
Exon 22 of 24ENSP00000418960.2
BRCA1
ENST00000470026.6
TSL:1
c.5348T>Cp.Met1783Thr
missense
Exon 21 of 23ENSP00000419274.2

Frequencies

GnomAD3 genomes
AF:
0.000519
AC:
79
AN:
152196
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00176
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000196
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00144
GnomAD2 exomes
AF:
0.000119
AC:
30
AN:
251442
AF XY:
0.0000883
show subpopulations
Gnomad AFR exome
AF:
0.00166
Gnomad AMR exome
AF:
0.0000578
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.0000486
AC:
71
AN:
1461844
Hom.:
0
Cov.:
31
AF XY:
0.0000468
AC XY:
34
AN XY:
727220
show subpopulations
African (AFR)
AF:
0.00155
AC:
52
AN:
33478
American (AMR)
AF:
0.000134
AC:
6
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39698
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86256
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53420
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1111968
Other (OTH)
AF:
0.000215
AC:
13
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.448
Heterozygous variant carriers
0
5
10
14
19
24
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000519
AC:
79
AN:
152314
Hom.:
0
Cov.:
31
AF XY:
0.000591
AC XY:
44
AN XY:
74478
show subpopulations
African (AFR)
AF:
0.00176
AC:
73
AN:
41562
American (AMR)
AF:
0.000196
AC:
3
AN:
15300
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5188
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4828
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68022
Other (OTH)
AF:
0.00142
AC:
3
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.488
Heterozygous variant carriers
0
4
9
13
18
22
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000216
Hom.:
0
Bravo
AF:
0.000518
ESP6500AA
AF:
0.00182
AC:
8
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.000173
AC:
21

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:4Benign:13
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Hereditary breast ovarian cancer syndrome Uncertain:1Benign:3
Apr 25, 2016
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Nov 01, 2021
Genetics Program, Instituto Nacional de Cancer
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:research

Apr 19, 2022
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:1Benign:2
Aug 05, 2009
Sharing Clinical Reports Project (SCRP)
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Feb 20, 2004
Breast Cancer Information Core (BIC) (BRCA1)
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

Oct 30, 2014
Pathway Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Hereditary cancer-predisposing syndrome Benign:3
May 10, 2021
Sema4, Sema4
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:curation

Dec 09, 2015
Color Diagnostics, LLC DBA Color Health
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Nov 18, 2014
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

not provided Benign:2
Jun 06, 2016
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: BRCA1 c.5348C>T is a missense variant that changes a conserved T to C, resulting in an amino acid change from Met to Thr at codon 1783 in the C-terminal BRCT domain of BRCA1. This variant is predicted to be damaging by 5/5 in-silico tools. Functional studies indicate that the variant slightly reduces BRCA1 structural stability, has intermediate phosphopeptide-binding activity, reduced transcriptional activity, and 66% of wild type BRCA1 HDR function.This variant was found in 21/121366 control chromosomes, predominantly observed in the African subpopulation at a frequency of 0.001929 (20/10368). This frequency is about 2 times the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005), suggesting this is likely a benign polymorphism found primarily in the populations of African origin. Although this variant was reported in multiple patients in the literature and databases, lack of co-segregation (McKean Cowdin_HumGen_2005) and multiple co-occurrences with pathogenic variants (UMD database) were found in some of these patients/families. In addition, multiple reputable sources classify this variant as likely benign/benign. Taken together, this variant was scored as Benign.

Jun 21, 2022
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

See Variant Classification Assertion Criteria.

Breast and/or ovarian cancer Uncertain:1
Oct 07, 2013
Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

Breast neoplasm Uncertain:1
Clinical and Functional Genomics Group, A.C.Camargo Cancer Center
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:research

not specified Benign:1
Jan 03, 2022
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Malignant tumor of breast Benign:1
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

The BRCA1 p.Met1783Thr variant was identified in 2 of 838 proband chromosomes (frequency: 0.002) from individuals or families with breast or ovarian cancer and was not identified in 192 control chromosomes from healthy individuals (McKean-Cowdin 2005, Silva 2014). The variant was also identified in dbSNP (ID: rs55808233) as "With other allele", ClinVar (classified as benign by Invitae, Ambry Genetics, and two other submitters; as likely benign by GeneDx, Color, and two other submitters; and as uncertain significance by five submitters), LOVD 3.0 (15x), and UMD-LSDB (2x as likely neutral). In UMD, the variant was reported with a co-occurring, pathogenic BRCA1 variants c.755_761del (p.Arg252LeufsX44) and c.-200_80del (p.Met1SerfsX13), increasing the likelihood that the p.Met1783Thr variant does not have clinical significance. The variant was identified in control databases in 45 of 277188 chromosomes at a frequency of 0.0002 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 41 of 24028 chromosomes (freq: 0.002, increasing the likelihood this could be a low frequency benign variant), Other in 2 of 6462 chromosomes (freq: 0.0003), and Latino in 2 of 34420 chromosomes (freq: 0.00006), while it was not observed in the European, Ashkenazi Jewish, East Asian, Finnish, or South Asian populations. Although the p.Met1783 residue is not conserved in mammals and other organisms, computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the M variant may impact the protein. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. There are conflicting results in the literature regarding the effect of this variant on the BRCA1 protein, specifically within the BRCT domain where this variant is located. Functional studies demonstrated that the variant may be moderately destabilizing to the protein folding (Drikos 2009, Glover 2006, Williams 2003, Rowling 2010) but that protein binding capabilities of the mutant protein were similar to the wild type (Drikos 2009, Glover 2006) and that the mutant protein retains between 50-70% DNA repair activity relative to the wild type (Gaboriau 2015, Lu 2015). In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.

Hereditary cancer Benign:1
Jan 23, 2024
Mendelics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.91
BayesDel_addAF
Benign
-0.0045
T
BayesDel_noAF
Pathogenic
0.21
CADD
Uncertain
24
DANN
Uncertain
0.99
DEOGEN2
Benign
0.38
T
Eigen
Uncertain
0.57
Eigen_PC
Uncertain
0.52
FATHMM_MKL
Pathogenic
0.97
D
LIST_S2
Uncertain
0.92
D
M_CAP
Pathogenic
0.64
D
MetaRNN
Uncertain
0.44
T
MetaSVM
Uncertain
0.22
D
MutationAssessor
Uncertain
2.3
M
PhyloP100
5.1
PrimateAI
Uncertain
0.56
T
PROVEAN
Pathogenic
-4.5
D
REVEL
Uncertain
0.63
Sift
Uncertain
0.0010
D
Sift4G
Uncertain
0.0020
D
Polyphen
0.99
D
Vest4
0.87
MVP
0.94
MPC
0.34
ClinPred
0.12
T
GERP RS
5.5
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.75
gMVP
0.85
Mutation Taster
=31/69
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
Splicevardb
2.0
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs55808233; hg19: chr17-41201196; API